Advertisement


Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis

2015 ASCO Annual Meeting

Advertisement

Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).



Related Videos

Breast Cancer

Nicholas C. Turner, MD, PhD, and Clifford A. Hudis, MD, on Results of the PALOMA3 Study on Hormone Receptor–Positive, HER2 Negative Metastatic Breast Cancer

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discuss fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed on prior endocrine therapy (Abstract LBA502).

Leukemia
Lymphoma

Asher Chanan-Khan, MD, Summarizes Ibrutinib, Bendamustine, and Rituximab in Previously Treated CLL/SLL

Asher Alban Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discusses an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).

Hematologic Malignancies

Ruben A. Mesa, MD, and James O. Armitage, MD, Results of the PERSIST-1 Study on Myelofibrosis

James O. Armitage, MD, of The University of Nebraska Medical Center, and Ruben A. Mesa, MD, of the Mayo Clinic, discuss pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).

Lung Cancer

David E. Gerber, MD, and James L. Mulshine, MD, on Bringing Genomic Discovery and Targeted Therapies to Early-Stage Lung Cancer

James L. Mulshine, MD, of Rush University Medical Center, and David E. Gerber, MD, of The University of Texas Southwestern Medical Center, discuss the ALCHEMIST trial, an NCI initiative to address the role of molecular testing and targeted therapies for earlier-stage lung disease (Abstract TPS7583).

Skin Cancer

Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD, on Oral Nicotinamide to Reduce Nonmelanoma Skin Cancers

Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).

Advertisement

Advertisement




Advertisement